Benitec Biopharma Inc. Cash and Restricted Cash
Benitec Biopharma Inc. (BNTC) had Cash and Restricted Cash of $180.09 million as of 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-09-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $180.09M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $184.88M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $188.90M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $94.59M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $180.09M 10-K · filed 2026-09-14 | |
| 2026-03-31 | $184.88M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $188.90M 10-Q · filed 2026-02-12 | |
| 2025-09-30 | $94.59M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $97.86M 10-K · filed 2026-09-14 | |
| 2025-03-31 | $103.45M 10-Q · filed 2026-05-14 | $103.65M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $78.34M 10-Q · filed 2026-02-12 | |
| 2024-09-30 | $67.91M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $50.93M 10-K · filed 2026-09-14 | |
| 2024-03-31 | $14.16M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $20.39M 10-Q · filed 2025-02-14 | |
| 2023-09-30 | $25.88M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $2.49M 10-K/A · filed 2026-03-20 | |
| 2023-03-31 | $6.57M 10-Q · filed 2024-05-13 | |
| 2022-12-31 | $10.55M 10-Q · filed 2024-02-13 | |
| 2022-09-30 | $16.55M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $4.08M 10-K · filed 2024-09-26 | |
| 2022-03-31 | $8.63M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $12.34M 10-Q · filed 2023-02-13 | |
| 2021-09-30 | $15.74M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $19.78M 10-K · filed 2023-09-21 | $19.77M 10-Q · filed 2022-05-16 |
| 2021-03-31 | $11.99M 10-Q · filed 2022-05-16 | |
| 2020-06-30 | $9.82M 10-K · filed 2022-09-02 | $9.80M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |